DM - oral Flashcards
Metformin (Biguinide) - MOA
inhibits glucose formation in liver, slightly reduces glucose absorption, increase glucose uptake
Metformin (Biguinide) - pharm
not metabolized, excreted by kidneys
Metformin (Biguinide) - AE
decreased appetite, N, diarrhea, start low and increase gradually, does NOT cause hypoglycemia
Metformin (Biguinide) - contraindications
HF and significant renal impairment
Metformin (Biguinide) - caution
use with caution in patients with liver dz, severe infection or h/o lactic acidosis
Sulfonylureas -names
glimepiride, glipizide, glyburide
Sulfonylureas - MOA
promote insulin secretion by pancreas
Sulfonylureas- AE
hypoglycemia
Sulfonylureas - precautions
- don’t give in preg or BF
- caution in patients with renal or hepatic dysfunction
Meglitinides (glinides) - MOA
stimulate insulin release
Meglitinides (glinides)- AE
hpoglycemia
Thiazolidinediones (TZD.Glitazone) - MOA
decrease insulin resistance, adjunct to metformin
Thiazolidinediones (TZD.Glitazone) - AE
URI, HA, sinusitis, myalgia, BBW - dont use in pts with HF, increase risk of bladder cancer, monitor for liver failure
alpha glucosidase Inhibitors (Acrabose) - MOA
delay absorption of carbs; can be used alone or adjunct
alpha glucosidase Inhibitors (Acrabose) - AE
flatulence, abd distension, diarrhea, r/o liver dysfunction with long term use
Dipeptidyl Peptidase - 4 Inhibitors (gliptins) - MOA
increase actions of incretin hormones, mono or adjunct
Dipeptidyl Peptidase - 4 Inhibitors (gliptins) - AE
URI, HA, rarely pancreatitis, hypersensitivity reactions
Sodium - Glucose Cotransporter 2 Inhibitors (SLGT2/Canagliflozin) - MOA
block reabsorption of filtered glucose which increases glucose in urine
Sodium - Glucose Cotransporter 2 Inhibitors (SLGT2/Canagliflozin) - AE
female genital infections, UTI, increase urination
Sodium - Glucose Cotransporter 2 Inhibitors (SLGT2/Canagliflozin) - interactions
rifampin, phenytoin, phenobarb (decreases levels)
r/o dehydration and hypotension with diuretics
Glucon like peptide 1 receptor Agonists (Byetta) - MOA
injectable, mimics incretin hormone, adjunct only
Glucon like peptide 1 receptor Agonists (Byetta) - AE
hypoglycemia, when given with sulfonyureas, N/V/D, renal impairment, hypersensitivity, weight loss, r/o developing antibodies, pancreatitis